Memantin Stada (Memantine Hydrochloride)

Memantin Stada acts on the glutamatergic pathway involved in neurodegeneration, providing symptomatic benefit in Alzheimer’s disease.

• Moderate to severe Alzheimer’s disease: improves cognition, daily functioning and overall clinical status in affected individuals.

• Memantine Hydrochloride binds to the NMDA (N‑methyl‑D‑aspartate) receptor at a site distinct from the glutamate binding site, acting as a non‑competitive antagonist. By reducing excessive calcium influx through the receptor channel, it limits excitotoxic neuronal injury while preserving normal synaptic transmission, thereby providing symptomatic relief in Alzheimer’s disease.

Memantin Stada may cause a range of adverse reactions. The most frequently reported events are generally mild to moderate in severity.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Headache: mild to moderate cranial pain.
• Constipation: reduced bowel movements.
• Confusion: transient disorientation.
• Fatigue: feeling unusually tired.
• Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects

• Seizures: convulsive episodes requiring medical attention.
• Arrhythmia: irregular heart rhythm.
• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Stevens‑Johnson syndrome: severe skin blistering.
• Hepatic dysfunction: abnormal liver enzymes.
• Psychosis: new or worsening hallucinations or delusions.

Before initiating therapy with Memantin Stada, consider the following safety measures.

• Renal impairment: adjust dose or monitor renal function.
• Hepatic impairment: use with caution in patients with liver disease.
• History of seizures: monitor closely for seizure activity.
• Concomitant NMDA antagonists: avoid combined use to prevent additive effects.
• Pregnancy and lactation: safety not established; weigh risks and benefits.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Memantin Stada can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid)

• Amantadine: additive NMDA antagonism may increase neurotoxicity.
• Other NMDA receptor antagonists: risk of excessive inhibition of glutamatergic signaling.
• High‑dose quinidine: may raise memantine plasma levels.

Moderate Interactions (Monitor Closely)

• Acetylcholinesterase inhibitors (e.g., donepezil): monitor for additive cognitive effects.
• CNS depressants (e.g., benzodiazepines): may enhance sedation.
• Antihypertensives: observe blood pressure for additive hypotensive effect.
• Diuretics: monitor electrolytes and renal function.
• NSAIDs: watch for increased risk of renal impairment.